Alvotech Q1 2026 Financial Results and FDA Acceptance of AVT16 BLA

Alvotech's June 2026 Form 6-K reports two key developments: (1) FDA acceptance of the Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) for intravenous administration, with Teva Pharmaceutical responsible for commercialization; (2) Q1 2026 financial results showing total revenues of $105.9 million (down from $132.8 million in Q1 2025) and adjusted EBITDA of $24.4 million. The company's unaudited financial statements show a modest profit of $1.0 million for Q1 2026, compared to $109.7 million in Q1 2025. The filing also includes forward-looking statements about regulatory approvals and financial projections, with management anticipating 2026 revenues of $650-700 million and adjusted EBITDA of $180-220 million. The company continues to focus on biosimilar development and manufacturing partnerships.